注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Xenetic Biosciences Inc是一家生物製藥公司。該公司專注於開發XCART,一種針對患者和腫瘤特异性新抗原的個性化嵌合抗原受體(CAR)T平臺科技。該公司正在推進針對單個患者惡性腫瘤細胞表面B細胞受體的細胞治療,用於治療B細胞性非霍奇金淋巴瘤。該公司利用其藥物遞送平臺PolyXen與生物技術和製藥公司合作。其產品線包括XCART和ErepoXen,或多唾液酸促紅細胞生成素。多唾液酸促紅細胞生成素使用其PolyXen平臺科技治療慢性腎病患者的貧血。它旨在通過延長治療藥物在體內的迴圈半衰期來降低給藥頻率。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Adam E. Logal | 45 | 2017 | Independent Chairman of the Board |
Jeffrey F. Eisenberg | 57 | 2016 | CEO, President & Director |
James Eric Callaway | 66 | 2017 | Independent Director |
Firdaus Jal Dastoor | 70 | 2014 | Independent Director |
Dmitry Dmitrievich Genkin | 56 | 2016 | Non-Executive Director |
Roger D. Kornberg | 76 | 2016 | Independent Director |
Alexey Andreevich Vinogradov | 52 | 2019 | Independent Director |
Matthew Frigault | - | 2019 | Member of Scientific Advisory Board |
Guenther Koehne | - | 2019 | Member of Scientific Advisory Board |
Grigory G. Borisenko | 54 | 2019 | Independent Non-Executive Director |
Maksim Mamonkin | - | 2020 | Member of Scientific Advisory Board |
Allan Tsung | - | 2022 | Member of Scientific Advisory Board |
Jonathan Spicer | - | 2022 | Member of Scientific Advisory Board |
Moshe Mizrahy | 70 | 2023 | Independent Non Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核